论文部分内容阅读
作者复习文献,认为目前采用单一或几种药物联合治疗晚期非小细胞型肺癌(NSGLC),疗效仍不满意,仅见客观缓解但生存期并无提高,中数生存期很少超过一年。单用长春花碱酰胺(Vindesine)对114例初治的NSCLC,有效率为23%,对周围神经毒性和骨髓抑制较少。单用顺铂对初治的NSCLC的有效率为19%,其主要为肾脏毒性及呕吐副作用。近年来采用长春花碱酰胺和大剂量顺铂120mg/m~2联合治
The author reviews the literature and believes that single-or multiple-drug combination therapy for advanced non-small-cell lung cancer (NSGLC) is currently not satisfactory, with only objective remission but no improvement in survival. The median survival is rarely more than one year. Using Vindesine alone in 114 cases of newly diagnosed NSCLC, the effective rate was 23%, and there was less peripheral neurotoxicity and bone marrow suppression. The effective rate of cisplatin alone for newly diagnosed NSCLC was 19%, which was mainly caused by renal toxicity and vomiting. In recent years, the use of vinblastine amide and large doses of cisplatin 120mg/m~2 joint treatment